Abstract | BACKGROUND: OBJECTIVES: To describe the effective approach to the management of dyslipidemia in patients with diabetes to allow providers and payers to become familiar with the treatment goals for all the components of lipoproteins, to correctly initiate appropriate lipid-lowering medications based on treatment goals and lipid-lowering capability, and to apply the data presented in lipid clinical trials to the treatment of patients with diabetes. SUMMARY: CONCLUSION:
LDL-C appears to have the greatest role in premature and early atherosclerosis and the development of CAD and must be treated as aggressively as hyperglycemia to reduce CAD risk. Becoming familiar with lipid treatment goals and the many therapies available today can help providers and payers implement the appropriate approach to managing diabetic dyslipidemia risk factors and reduce the burden of this disease.
|
Authors | Marsha J Daniel |
Journal | American health & drug benefits
(Am Health Drug Benefits)
Vol. 4
Issue 5
Pg. 312-22
(Sep 2011)
ISSN: 1942-2962 [Print] United States |
PMID | 25126359
(Publication Type: Journal Article, Review)
|